Filing Details
- Accession Number:
- 0000899243-17-024683
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-25 16:05:31
- Reporting Period:
- 2017-10-23
- Accepted Time:
- 2017-10-25 16:05:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1631650 | Aimmune Therapeutics Inc. | AIMT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1222037 | Md C Daniel Adelman | Aimmune Therapeutics, Inc. 8000 Marina Boulevard, Suite 300 Brisbane CA 94005-1884 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2017-10-23 | 10,000 | $11.45 | 10,000 | No | 4 | M | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2017-10-23 | 5,530 | $33.25 | 4,470 | No | 4 | S | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2017-10-23 | 1,470 | $34.27 | 3,000 | No | 4 | S | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2017-10-23 | 3,000 | $35.46 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2017-10-23 | 10,000 | $0.00 | 10,000 | $11.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 230,000 | 2026-06-24 | No | 4 | M | Direct |
Footnotes
- This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $32.83 to $33.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from $33.84 to $34.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The transaction was executed in multiple trades in prices ranging from $34.87 to $35.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 16, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Billionaire Hedge Funds
